Image
NEW YORK – November 13, 2026 -- Immunic, Inc. (Nasdaq: IMUX) says top-line data from its two Phase 3 ENSURE trials of vidofludimus calcium in relapsing
Published by:
fairsonline_team
Industries
NEW YORK – November 13, 2026 -- Immunic, Inc. (Nasdaq: IMUX) says top-line data from its two Phase 3 ENSURE trials of vidofludimus calcium in relapsing